KR890014114A - 신경이완제 투여와 연관된 추체외로(extrapyramidal) 부작용의 치료방법 - Google Patents

신경이완제 투여와 연관된 추체외로(extrapyramidal) 부작용의 치료방법 Download PDF

Info

Publication number
KR890014114A
KR890014114A KR1019890003247A KR890003247A KR890014114A KR 890014114 A KR890014114 A KR 890014114A KR 1019890003247 A KR1019890003247 A KR 1019890003247A KR 890003247 A KR890003247 A KR 890003247A KR 890014114 A KR890014114 A KR 890014114A
Authority
KR
South Korea
Prior art keywords
compound
methanol
piperidinyl
phenyl
piperidine
Prior art date
Application number
KR1019890003247A
Other languages
English (en)
Inventor
지. 팔프레이만 마이클
에이.카르 알버트
Original Assignee
게리 디.스트리트
메렐 다우 파마슈티칼즈 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 게리 디.스트리트, 메렐 다우 파마슈티칼즈 인코포레이티드 filed Critical 게리 디.스트리트
Publication of KR890014114A publication Critical patent/KR890014114A/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

내용 없음.

Description

신경이완제 투여와 연관된 추체외로(extrapyramidal) 부작용의 치료방법
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (20)

  1. 신경이완제 투여와 연관된 추체외로(extrapyramidal) 부작용의 치료가 필요한 환자에게 항-EPS 양의 일반식(Ⅰ)의 화합물 및 이의 약제학적으로 허용되는 산부가염을 투여함을 특징으로 하여, 상기 부작용을 치료하는 방법.
    상기식에서,R1,R2,R3및R4는 각각 독립적으로 수소, C1-6알킬그룹, 할로겐, 트리플루오로메틸, 하이드록시, C1-6알콕시그룹 및 아미노 그룹으로 구성된 그룹중에서 선택되고, n은 2,3, 또는 4이다.
  2. 제1항에 있어서, 화합물이 α-페닐-1-(2-펜에틸)-4-피페리딘 메탄올인 방법.
  3. 제1항에 있어서, 화합물이 α-페닐-1-(3-펜프로필)-4-피페리딘 메탄올인 방법.
  4. 제1항에 있어서, 화합물이 α-(4-메틸페닐)-1-(2-펜에틸)-4-피페리딘 메탄올인 방법.
  5. 제1항에 있어서, 화합물이 α-(4-메톡시페닐)-1-(2-펜에틸)-4-피페리딘 메탄올인 방법.
  6. 제1항에 있어서, 화합물이 α-(3,5-디메틸페닐)-1-(2-펜에틸)-4-피페리딘 메탄올인 방법.
  7. 제1항에 있어서, 화합물이 α-(3-(트리플루오로메틸)페닐)-1-(2-펜에틸)-4-피페리딘 메탄올인 방법.
  8. 제1항에 있어서, 화합물이 α-(2,3-디메톡시페닐)-1-(2-펜에틸)-4-피페리딘 메탄올인 방법.
  9. 제1항에 있어서, 화합물이 α-(4-플루오로페닐)-[1-(2-페닐에틸)-4-피페리디닐]-메탄올인 방법.
  10. 제1항에 있어서, 화합물이 α-페닐-[1-(4-페닐부틸)-4-피페리디닐]-메탄올인 방법.
  11. 제1항에 있어서, 화합물이 α-(3,4-디메톡시페닐)-[1-(2-페닐에틸)-4-피페리디닐]-메탄올인 방법.
  12. 제1항에 있어서, 화합물이 α-페닐-[1-(4-아미노페닐에틸)-4-피페리디닐]메탄올인 방법.
  13. 제1항에 있어서, 화합물이 α-페닐-[1-(4-메톡시페닐에틸)-4-피페리디닐]-메탄올인 방법.
  14. 제1항에 있어서, 화합물이 α-(4-메톡시페닐)-[1-(4-메톡시페닐에틸)-4-피페리디닐]-메탄올인 방법.
  15. 제1항에 있어서, 화합물이 α-(2,3-디메톡시페닐)-[1-(4-메톡시페닐에틸)-4-피페리딘]-메탄올인 방법.
  16. 제1항에 있어서, 화합물이 α-페닐-[1-(4-메톡시페닐에틸)-4-피페리디닐]메탄올인 방법.
  17. 제1항에 있어서, 화합물이 α-페닐-[1-(4-플루오로페닐에틸)-4-피페리디닐]메탄올인 방법.
  18. 제1항에 있어서, 화합물이 α-(4-하이드록시페닐)-[1-(2-페닐에틸)-4-피페리디닐]-메탄올인 방법.
  19. 제1항에 있어서, 화합물이 α-(3,4-디하이드록시페닐)-[1-(2-페닐에틸)-4-피페리디닐]-메탄올인 방법.
  20. 제1항에 있어서, 화합물이 α-(3,4-디클로로페닐)-[1-(2-페닐에틸)-4-피페리딘 메탄올인 방법.
    ※ 참고사항:최초출원 내용에 의하여 공개하는 것임.
KR1019890003247A 1988-03-17 1989-03-16 신경이완제 투여와 연관된 추체외로(extrapyramidal) 부작용의 치료방법 KR890014114A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16926988A 1988-03-17 1988-03-17
US169269 1988-03-17

Publications (1)

Publication Number Publication Date
KR890014114A true KR890014114A (ko) 1989-10-21

Family

ID=22614934

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019890003247A KR890014114A (ko) 1988-03-17 1989-03-16 신경이완제 투여와 연관된 추체외로(extrapyramidal) 부작용의 치료방법

Country Status (6)

Country Link
EP (1) EP0337136A3 (ko)
JP (1) JPH01275530A (ko)
KR (1) KR890014114A (ko)
AU (1) AU614117B2 (ko)
DK (1) DK128589A (ko)
ZA (1) ZA891901B (ko)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8908085D0 (en) * 1989-04-11 1989-05-24 Lundbeck & Co As H New therapeutic use
US6004980A (en) * 1990-06-01 1999-12-21 Merrell Pharmaceuticals, Inc. (+)-α-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol
DE69105501T2 (de) * 1990-06-01 1995-04-13 Merrell Dow Pharma (+)-alpha-(2,3 dimethoxyphenyl)-1-[2-(fluorophenyl)ethyl]-4-piperidinmethanol.
US5231099A (en) * 1991-04-15 1993-07-27 Du Pont Merck Pharmaceutical Company Use of sigma receptor antagonists to enhance the effects of antipsychotic drugs
US5618824A (en) * 1994-03-09 1997-04-08 Merrell Pharmaceuticals Inc. Treatment of obsessive-compulsive disorders with 5-HT2 antagonists
ZA9610736B (en) 1995-12-22 1997-06-27 Warner Lambert Co 2-Substituted piperidine analogs and their use as subtypeselective nmda receptor antagonists
ZA9610738B (en) 1995-12-22 1997-06-24 Warner Lambert Co Subtype selective nmda receptor ligands and the use thereof
ZA9610741B (en) 1995-12-22 1997-06-24 Warner Lambert Co 4-Substituted piperidine analogs and their use as subtype selective nmda receptor antagonists
ZA9610745B (en) * 1995-12-22 1997-06-24 Warner Lambert Co 4-Subsituted piperidine analogs and their use as subtype selective nmda receptor antagonists
EP0796619A1 (en) * 1996-03-21 1997-09-24 Merrell Pharmaceuticals Inc. Use of (+)-alpha-(2,3-dimethoxyphenyl)-1-(2-(4-fluorophenyl)ethyl)-4-piperidinemethanol in treating depressive disorders and bipolar disorders
US6028083A (en) * 1997-07-25 2000-02-22 Hoechst Marion Roussel, Inc. Esters of (+)-α-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl) ethyl]-4-piperidinemethanol
US6713627B2 (en) 1998-03-13 2004-03-30 Aventis Pharmaceuticals Inc. Processes for the preparation of (R)-α-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol
US6277864B1 (en) 1998-08-28 2001-08-21 Aventis Pharmaceuticals Inc. Use of R- +)-α-(2,3-dimethoxyphenyl-1-[2-(4-fluorophenyl) ethyl]-4-piperidinemethanol for the treatment of sleep disorders
US6939879B2 (en) 1998-08-28 2005-09-06 Aventis Pharmaceuticals Inc. Use of R (+)-α-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol for the treatment of substance induced insomnia
DE102004010132A1 (de) 2004-02-27 2005-09-15 Merck Patent Gmbh Piperidinderivate

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1280421C (en) * 1985-07-02 1991-02-19 Albert A. Carr 1,4-disubstituted piperidinyl derivatives
US5093341A (en) * 1987-12-17 1992-03-03 Merrell Dow Pharmaceuticals Inc. N-aralkyl piperidine derivatives useful as antithrombolytic agents

Also Published As

Publication number Publication date
DK128589D0 (da) 1989-03-16
AU3133889A (en) 1989-09-21
AU614117B2 (en) 1991-08-22
JPH01275530A (ja) 1989-11-06
DK128589A (da) 1989-09-18
EP0337136A2 (en) 1989-10-18
ZA891901B (en) 1989-11-29
EP0337136A3 (en) 1990-09-05

Similar Documents

Publication Publication Date Title
KR890014114A (ko) 신경이완제 투여와 연관된 추체외로(extrapyramidal) 부작용의 치료방법
RU2000129161A (ru) Производное 1-[(1-замещенного-4-пиперидинил)метил]-4-пиперидина, способ его получения, фармацевтическая композиция, содержащая указанное соединение, и промежуточный продукт
KR890000465A (ko) 환상 아민 화합물
EA005924B1 (ru) Ассоциация или комбинация антагониста рецептора cb1 и сибутрамина, содержащие их фармацевтические композиции и их применение для лечения ожирения
KR950016725A (ko) 폐 고혈압성 질병을 억제하는 방법
KR950010892A (ko) 자궁 섬유증 억제 방법
KR950016732A (ko) 피부 및 질의 위축 억제방법
NO20003671L (no) 4-(2-keto-1-benzimidazolinyl)piperidin-forbindelser som orl1- reseptor agonister
KR900006328A (ko) 2-아제티디논 유도체
KR890011840A (ko) 1,4-이치환 -피페리디닐 화합물
KR950016731A (ko) 지루 및 좌창의 억제 방법
KR890009398A (ko) 불안증 치료방법
KR950016723A (ko) 자가면역 질병의 억제 방법
KR920006316A (ko) 칼슘 흡수 억제제
KR950016740A (ko) 조직의 불완전한 회복을 저해하는 방법
KR950016724A (ko) 폐경기 후 여성의 리비도를 증가시키는 방법
KR950010887A (ko) 연골 퇴화 억제 방법
KR950016729A (ko) 유방 질환의 억제 방법
KR890011596A (ko) 불면증 치료용 의약품의 제조에 있어서 1,4-이치환-피페리디닐 화합물의 용도
KR950016742A (ko) 폐경후 여성의 씨엔에스 질환을 억제하는 방법
KR950016735A (ko) 터너 증후군의 억제 방법
KR910004191A (ko) 신질환치료제
KR900018091A (ko) 진경제
KR950016734A (ko) 성적 조숙증의 억제방법
KR890007735A (ko) 섬유성 근통증 치료방법

Legal Events

Date Code Title Description
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid